BRAF and neoplasm: For example, information on clinical features (e.g., ECOG performance status, KRAS/BRAF mutation, primary tumor location) and therapeutic regimens (e.g., FOLFIRI, FOLFOX) given in combination with biological therapy were not available in administrative databases.